Evidence map›Paper›PMID 33035457›Full record

Trial reportThe Lancet. Oncology2020

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.

Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos, Pamela McKay, Tycel Phillips, Sarit Assouline, Connie Lee Batlevi, Phillip Campbell, Vincent Ribrag, Gandhi Laurent Damaj and 11 more

Open access · greenAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Lancet. Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 356 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
356citing papers in PubMed, 8 pooled it
47.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

356 citing papers in PubMed, 8 syntheses or guidelines pooled it, 569 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. A genetic profiling guideline to support diagnosis and clinical management of lymphomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Guideline
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

296 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 18 institutions in 6 countries.

Franck MorschhauserGroupe de Recherche sur les formes Injectables et les Technologies Associées, CHU de Lille, Université de Lille, Lille, France. Electronic address: franck.morschhauser@chru-lille.fr.
Hervé TillyDepartment of Hematology and INSERM U1245, Centre Henri Becquerel and Rouen University, Rouen, France.
Aristeidis ChaidosCentre for Haematology, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, Hammersmith Hospital & Imperial College Healthcare NHS Trust, London, UK.
Pamela McKayDepartment of Hematology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
Tycel PhillipsDivision of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.
Sarit AssoulineDivision of Hematology, Jewish General Hospital, Montreal, QC, Canada; Department of Oncology, McGill University, Montreal, QC, Canada.
Connie Lee BatleviDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Phillip CampbellDepartment of Clinical Haematology, Barwon Health, University Hospital Geelong, Geelong, VIC, Australia.
Vincent RibragHematology Department, Gustave Roussy, Villejuif, France.
Gandhi Laurent DamajHematology Institute, Hematologie Clinique, University Hospital School of Medicine, Caen, France.
Michael DickinsonDepartment of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Wojciech JurczakDepartment of Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland.
Maciej KazmierczakDepartment of Hematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poznań, Poland.
Stephen OpatHaematology Department, Monash University, Melbourne, VIC, Australia.
John RadfordDepartment of Medical Oncology, University of Manchester, Manchester, UK; NIHR Manchester Clinical Research Facility, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Manchester, UK.
Anna SchmittDepartment of Hematology, Institut Bergonié, Bordeaux, France.
Jay YangClinical Development, Epizyme, Cambridge, MA, USA.
Jennifer WhalenClinical Development, Epizyme, Cambridge, MA, USA.
Shefali AgarwalClinical Development, Epizyme, Cambridge, MA, USA.
Deyaa AdibClinical Development, Epizyme, Cambridge, MA, USA.
Gilles SallesDepartment of Hematology, Lyon-Sud Hospital, University of Lyon, Pierre-Bénite, France.
Epizyme (United States) · USBarwon Health · AUBeatson West of Scotland Cancer Centre · GBHammersmith Hospital · GBInserm · FRInstitut Bergonié · FRInstitut Gustave Roussy · FRMcGill University · CAMemorial Sloan Kettering Cancer Center · USMonash University · AUPoznan University of Medical Sciences · PLThe Maria Sklodowska-Curie National Research Institute of Oncology · PLThe Royal Melbourne Hospital · AUUniversité Claude Bernard Lyon 1 · FRUniversité de Caen Normandie · FRUniversité de Lille · FRUniversity of Manchester · GBUniversity of Michigan–Ann Arbor · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundActivating mutations of EZH2, an epigenetic regulator, are present in approximately 20% of patients with follicular lymphoma. We investigated the activity and safety of tazemetostat, a first-in-class, oral EZH2 inhibitor, in patients with follicular lymphoma.

methodsThis study was an open-label, single-arm, phase 2 trial done at 38 clinics or hospitals in France, the UK, Australia, Canada, Poland, Italy, Ukraine, Germany, and the USA. Eligible patients were adults (≥18 years) with histologically confirmed follicular lymphoma (grade 1, 2, 3a, or 3b) that had relapsed or was refractory to two or more systemic therapies, had an Eastern Cooperative Oncology Group performance status of 0-2, and had sufficient tumour tissue for central testing of EZH2 mutation status. Patients were categorised by EZH2 status: mutant (EZH2

findingsBetween July 9, 2015, and May 24, 2019, 99 patients (45 in the EZH2

interpretationTazemetostat monotherapy showed clinically meaningful, durable responses and was generally well tolerated in heavily pretreated patients with relapsed or refractory follicular lymphoma. Tazemetostat is a novel treatment for patients with follicular lymphoma.

fundingEpizyme.

Indexed as

AdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBenzamidesBiphenyl CompoundsEnhancer of Zeste Homolog 2 ProteinFemaleHumansLymphoma, FollicularMaleMiddle AgedMorpholinesMutationNeoplasm Recurrence, LocalProgression-Free SurvivalAntibodies, Monoclonal, HumanizedBenzamidesBiphenyl CompoundsEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanMorpholinesPyridonestazemetostat

Identifiers

PMID33035457
PMCPMC8427481
OpenAlexW3092484545

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.